

Response to Reviews

23th of February 2016

Dear Editor,

We have studied the valuable comments from you, the assistant editor and reviewers carefully, and tried our best to revise the manuscript. The point to point responds to the reviewer's comments are listed as following:

Responds to the reviewer's comments:

Comment: Qian et al. investigated the effect of combined Administration of TACE and GRGDSP-conjugated nanoparticles in a rat model of an implanted HCC. The study appears to be well performed and the manuscript is well written. This study is more a pilot study rather than an exhaustive study, but is worth publishing as it is. Subsequent studies should be performed to localize the nanoparticles shortly after the administration and to investigate if the RGD peptide alters the distribution of the nanoparticles. Perhaps the authors should make more clear if and how this study can be translated to patients.

Response:

Dear Professor Gong,

Thanks for your reading this letter firstly.

I am the corresponding author of the paper "Transarterial Administration of Integrin Inhibitor Nanoparticles combined with Transarterial Chemoembolization for Treating Hepatocellular Carcinoma in Rat Model ", ESPS Manuscript NO: 23591. Thank you for your kind attention to consider our work in combined Administration of TACE and GRGDSP-conjugated nanoparticles in a rat model of an implanted HCC. And thank you again for your encouragement and advice, you suggest us to perform more subsequent studies. We just now had prepared fluorescently labeled GRGDSP nanoparticles and we are going to use fluorescence microscope to observe and investigate whether the RGD peptide can distributed from the artery to the tumor. Our study results may be reported in the next manuscript to the World Journal of Gastroenterology.

Thank you very much for your consideration.

Sincerely yours,

Jun Qian, M.D.